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A b s t r a c t
Background: Metformin is one of the antihyperglycaemic drugs, reducing the risk of major cardiovascular events, including 
fatal ones. Although it is formally contraindicated in moderate and severe functional stages of heart failure (HF), it is commonly 
used in patients with concomitant type 2 diabetes mellitus (T2DM).
Aim: We sought to evaluate the effect of metformin and T2DM on total mortality and hospitalisation rates in patients with HF.
Methods: This retrospective analysis included 1030 adult patients (> 18 years) with HF from the Polish section of the HF 
Long-Term Registry (enrolled between 2011 and 2014). Patients with T2DM (n = 350) were identified and divided into two 
groups: those receiving metformin and those not. Both groups were subjected to one-year follow-up.
Results: Mean patient age was 65.3 ± 13.5 years, with the predominance of male sex (n = 726) and obesity (mean body 
mass index 30.3 ± 5.5 kg/m2) and mean left ventricular ejection fraction was 34.3% ± 14.1%. Among patients with T2DM 
(n = 350) only 135 (38.6%) were treated with metformin. During one-year follow-up, 128 patients with HF died, of whom 
53 had T2DM (15.1% vs. 10.9%, hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.87–0.91, p = 0.045). Metformin 
was associated with a lower mortality rate compared to other antihyperglycaemic agents (9.6% vs. 18.6%, HR 0.85; 95% CI 
0.81–0.89, p = 0.023). There were no significant differences in the hospitalisation rate, including that due to HF decompensation, 
among patients treated with metformin and the remainder (53.5% vs. 40.0%, respectively HR 0.93, 95% CI 0.82–1.04, p = 0.433).
Conclusions: Metformin treatment in patients with different degrees of HF and T2DM is associated with a reduction in 
mortality and does not affect the hospitalisation rate.
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INTRODUCTION
Heart failure (HF) is often an independent consequence of 
diabetes mellitus (DM), and it may also be a concurrent dis-
order. Yang et al. [1] have reported that after coronary artery 
disease, DM is the second most common pathology related 
to HF, doubling the risk of this disease. It has been suggested 
that HF is usually an initial manifestation of cardiovascular 
disease in patients with type 2 diabetes mellitus (T2DM) [2]. 
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Conversely, the severity of HF was associated with a slightly 
increased risk of developing DM [3]. 
Insulin resistance plays a pivotal role in the development 
of a varied cluster of metabolic abnormalities, including T2DM 
and associated cardiovascular diseases. It has been found 
that insulin resistance alters the systemic and neurohumoral 
environment, leading to the growth of fibrous tissue. This dam-
aging process increases myocardial stiffness and contributes 
to left ventricular diastolic dysfunction, known as “diabetic 
cardiomyopathy” [4]. 
Metformin is the most widely used oral antihypergly-
caemic agent and it is the preferred initial pharmacological 
agent for T2DM patients. It is well known that metformin 
improves insulin sensitivity, mainly in skeletal muscles and the 
liver, and in addition to its glucose-lowering effect, the drug 
appears to possess a cardioprotective potential. A number 
of experimental and clinical studies have demonstrated that 
metformin has a beneficial effect on lipid, atherothrombic, 
and inflammatory profiles, endothelial function, oxidative 
stress, and antiproliferative and neuroprotective properties [5]. 
Due to the risk of lactic acidosis, the Food and Drug Ad-
ministration classified HF as a contraindication to metformin 
therapy [6]. However, a recent placebo-controlled trial sug-
gests that a number of possible benefits may be derived from 
this drug with regard to its effect on HF and DM [7]. Therefore, 
the aim of this retrospective analysis was to assess whether 
metformin treatment and the presence of T2DM affect overall 
mortality and all-cause hospitalisation rates in patients with 
HF and T2DM during a one-year follow-up period.
METHODS
ESC HF Long-Term Registry
The data was obtained from a Polish population of the pro-
spective, multicentre, observational study of the European 
Society of Cardiology (ESC) HF Long-Term Registry. A list of all 
participating centres is provided in Acknowledgements. The 
study was approved by the Bioethics Committee in 2011. 
The study included 1126 patients with HF enrolled in the 
years 2011–2014. Patients with new onset, worsening, or chronic 
HF (CHF) were included by participating centre physicians after 
obtaining written informed patient’s consent both in hospital 
(acute and worsening of HF) and outpatient clinics (CHF). 
Analysis of the effect of metformin  
use and the presence of T2DM
Our retrospective analysis comprised 1030 patients (726 men, 
mean age 65.3 ± 13.5 years) in various New York Heart As-
sociation (NYHA) functional classes. All patients who were 
enrolled in hospital and died before discharge or patients lost 
to follow-up were excluded from analysis (n = 96).
Heart failure diagnosis was based on symptoms, physical 
examination, documented aetiology (ischaemic, hypertension, 
dilated cardiomyopathy, valve disease, tachycardia-related 
cardiomyopathy, and others), and echocardiography ac-
cording to the clinical judgement of the physicians from 
participating centres. No specific exclusion criteria were given 
in the HF Long-Term Registry protocol, except age under 
18 years. Exercise tolerance was estimated according to the 
NYHA classification.
A detailed history of HF, comorbidities, and actual treat-
ment was collected from each patient during first contact. 
Additionally, physical examination, measurement of basic 
anthropometric and laboratory parameters and blood pres-
sure, electrocardiography (ECG), and echocardiography were 
performed. Patients were asked about the presence of glucose 
metabolism disorders. T2DM was diagnosed on the basis of 
medical documentation, used antihyperglycaemic agents 
(insulin, metformin, glitazones, incretins, sulphonylurea, 
and others) or diagnostic procedure during the first contact 
with the patient, according to the current guidelines of the 
Polish Diabetes Association. Chronic kidney dysfunction and 
hepatic dysfunction were diagnosed on the basis of medi-
cal documentation.
Patients with and without T2DM were identified (T2DM 
and non-T2DM groups, respectively). The former group was 
further subdivided as follows: group 1 — patients receiving 
metformin in monotherapy or in combination with other anti-
hyperglycaemic drugs (T2DM-M); group 2 — patients treated 
with antidiabetic agents other than metformin (T2DM-NM).
Patients were included in the metformin group if they had 
been treated with it in an outpatient clinic, during hospitalisa-
tion, or after discharge from hospital.
Participants were subjected to one-year follow-up. The 
follow-up data were collected by phone, during a visit in an 
outpatient clinic or during hospitalisation. A detailed history 
of rehospitalisations and vital status was collected. Hospitali-
sation rates were divided into five categories: related to HF, 
non-HF cardiac cause, vascular cause (peripheral vascular 
disease, stroke, embolism, aneurysms), renal dysfunction, 
and other causes.
Statistical analysis
Statistical analyses were performed with STATISTICA 12 Soft-
ware (StatSoft Inc., Tulsa, OK, USA). Probability distribution of 
continuous values was tested with Lillefors and Shapiro-Wilk 
tests. Because the distribution was found to be non-normal, 
the Mann-Whitney U test was performed to analyse the 
investigated values. The c2 test was used to compare non-
parametric values, including NYHA classification, while 
univariate regression analysis was performed for parametric 
values. Data were presented as mean ± standard deviation, 
and p-values < 0.05 were considered statistically significant.
RESULTS
Demographic and baseline clinical data
Out of 1030 patients with HF, 350 were identified as having 
T2DM. The whole population had mean body mass index 
(BMI) of 30.3 ± 5.5 kg/m2 and mean value of left ventricular 
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ejection fraction (LVEF) was 34.3% ± 14.1% (Table 1). In both 
groups with HF: T2DM and non-T2DM (N-T2DM), the male 
population prevailed, and sex distribution was similar (n = 488, 
71.8% and n = 238, 68.0%, respectively, p = 0.254) (Table 2).
The N-T2DM patients demonstrated a lower NYHA class 
at discharge from hospital, at first visit to the outpatient clinic 
and at one-year follow-up. Additionally, while this score was 
similar in both T2DM subgroups at discharge from hospital, at 
first visit to the outpatient clinic, and at the one-year follow-up, 
the T2DM-M group presented a lower NYHA class on admis-
sion to hospital (Table 3).
Most of the results were obtained from hospitalised 
T2DM patients (135 of 350, 38.6%) treated with metformin. 
Metformin was more frequently used on inpatients than on 
those in outpatient clinics (65% vs. 35%) (Fig. 1).
Interfering factors
The T2DM patients tended to be older with lower height, 
systolic blood pressure, body weight, and BMI than N-T2DM 
patients (Table 1). Moreover, this study group demonstrated 
a more frequent history of myocardial infarction or angina, 
peripheral vascular disease, valvular surgery, hypertension 
treatment, chronic kidney dysfunction (CKD), and current 
malignant disease than the N-T2DM group with HF (Table 2).
In the T2DM group, those receiving metformin dem-
onstrated a lower prevalence of CKD (n = 27, 20.0% 
vs. n = 80, 37.2%; p < 0.001) and hepatic dysfunction 
(n = 2, 6.5% vs. n = 14, 1.5%; p = 0.028), and higher body 
mass (90.2 ±19.1 kg vs. 84.0 ± 15.3 kg; p = 0.003) and 
BMI (31.4 ± 6.0 kg/m2 vs. 29.6 ± 5.1 kg/m2, p = 0.003) than 
T2DM-NM patients (Table 2).
Mortality and hospitalisation rates
Of the whole HF population 128 (12.4%) patients had died by 
the time of the one-year follow-up. More patients with T2DM 
(n = 53, 15.1%) had died than N-T2DM patients (n = 75, 
10.9%, hazard ratio [HR] 0.89; 95% confidence interval [CI] 
0.87–0.91; p = 0.045).
Metformin treatment was associated with lower mortality 
rates: 9.6% (n = 13) for treated patients compared to 18.6% 
(n = 40) for T2DM-NM patients (HR 0.85; 95% CI 0.81–0.89; 
p = 0.023; Fig. 2, Table 4).
Hospitalisation rates were lower for T2DM patients for 
12 months, at 92.8% (n = 325), compared to 78.2% for 
N-T2DM patients (n = 200, p = 0.01), with no significant 
differences regarding hospitalisation rates by cause of hospi-
talisation (Table 4).
For the T2DM-M and T2DM-NM subgroups total hospi-
talisation rates were similar, but the hospitalisation rate due 
to non-HF cardiac cause was higher in the metformin group 
(n = 43, 31.9%) than in the non-metformin group (n = 36, 
16.7%; p = 0.042; Fig. 3, Table 4).
There was no difference in mortality rates in terms of 
presence of CKD and hepatic dysfunction in N-T2DM pa-
tients. Likewise, in T2DM-M patients the analysis showed that 
these mortality rates were similar. However, we found that 
they were higher in T2DM-NM patients with CKD (n = 14, 
23.8% vs. n = 21, 15.6%; p = 0.012) and hepatic dysfunc-
tion (n = 5, 35.7% vs. n = 35, 17.4%; p = 0.01; Table 5).
DISCUSSION
Metformin has long been considered as an initial pharmacother-
apy in the treatment of hyperglycaemia in patients with T2DM 
recommended by all diabetes associations. Miura et al. [8] 
found that about 44% of patients with CHF were treated with 
antidiabetic drugs such as metformin, and 11.5% had various 
forms of insulin regimens. In our study, 38.6% of patients with 
T2DM, mainly requiring hospitalisation, were treated with 
metformin. It should be emphasised that the majority of these 
patients were not using metformin. 
Metformin not only has an antihyperglycaemic effect, 
but also other important effect, especially on the cardiovas-
Table 1. Baseline parametric characteristics of the study population selected by the presence of type 2 diabetes mellitus and 
metformin treatment
T2DM-NM T2DM-M N-T2DM p (T2DM-NM vs. T2DM-M) p (N-T2DM vs. T2DM)
Age [years] 68.1 ± 10.8 64.5 ± 10.5 62.3 ± 14.5 0.051 < 0.001
Height [cm] 168.4 ± 8.5 169.1 ± 9.8 170.5 ± 8.3 0.465 0.003
Weight [kg] 84.0 ± 15.3 90.2 ± 19.1 80.2 ± 16,.5 0.003 < 0.001
BMI [kg/m2] 29.6 ± 5.1 31.4 ± 6.0 27.5 ± 4.7 0.003 < 0.001
Heart rate [bpm] 82.3 ± 20.3 80.7 ± 19.2 80.3 ± 21.9 0.528 0.375
Systolic BP [mmHg] 127.3 ± 24.0 128.8 ± 26.7 122.9 ± 20.5 0.584 0.002
Diastolic BP [mmHg] 76.1 ± 12.9 77.6 ± 14.7 75.8 ± 12.1 0.357 0.327
Last known LVEF [%] 33.1 ± 14.2 36.2 ± 13.8 35.6 ± 13.8 0.072 0.229
Data are shown as mean ± standard deviation. BMI — body mass index; BP — blood pressure; LVEF — left ventricular ejection fraction; T2DM — 
type 2 diabetes mellitus; T2DM-M — patients with type 2 diabetes mellitus treated with metformin; T2DM-NM — patients with type 2 diabetes 
mellitus treated without metformin; N-T2DM — patients without type 2 diabetes mellitus
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Female 71 (33.0) 41 (30.4) 192 (28.2)
Male 144 (67.0) 94 (69.6) 488 (71.8)
Comorbidities:
MI/angina 129 (60.0) 80 (59.3) 319 (46.9) 0.891 < 0.001
CABG 24 (11.1) 19 (14.1) 69 (10.1) 0.419 0.255
PCI 66 (30.7) 47 (34.8) 186 (27.4) 0.314 0.267
Stroke/TIA 28 (13.0) 15 (11.1) 68 (10.0) 0.596 0.224
Peripheral vascular disease 41 (19.1) 25 (18.5) 70 (10.3) 0.898 < 0.001
Valvular surgery 8 (3.7) 8 (5.9) 69 (10.2) 0.336 0.001
Hypertension treatment 164 (76.3) 101 (74.8) 385 (56.6) 0.677 < 0.001
VTE 10 (4.7) 7 (5.2) 38 (5.6) 0.821 0.705
COPD 40 (18.6) 16 (11.9) 94 (13.8) 0.093 0.539
CKD 80 (37.2) 27 (20.0) 135 (19.9) < 0.001 < 0.001
Current malignant disease 13 (6.1) 3 (2.2) 16 (2.3) 0.095 0.046
Hepatic dysfunction 14 (6.5) 2 (1.5) 35 (5.1) 0.028 0.731
Sleep apnoea 11 (5.1) 11 (8.1) 32 (4.7) 0.373 0.275
Depression 11 (5.1) 6 (4.4) 30 (4.4) 0.776 0.723
Parkinson’s disease 4 (1.9) 0 4 (0.6) 0.111 0.324
Rheumatoid arthritis 13 (6.1) 3 (2.2) 20 (2.9) 0.095 0.161
Thyroid dysfunction 40 (18.4) 23 (17.0) 88 (13.0) 0.733 0.693
Data are shown as number (percentage). CABG — coronary artery bypass graft; CKD — chronic kidney dysfunction; COPD — chronic obstructive 
pulmonary disease; MI — myocardial infarction; PCI — percutaneous coronary intervention; TIA — transient ischaemic attacks; VTE — venous 
thromboembolism; other abbreviations — see Table 1
Table 3. New York Heart Association (NYHA) class at admission to hospital, at discharge/first visit in outpatient clinic, and at one-
-year follow-up in heart failure patients
NYHA class p (T2DM-NM 
vs. T2DM-M)
p (N-T2DM 
vs. T2DM)I II III IV
Admission to the hospital:
T2DM-NM 0 32 (15) 103 (48) 80 (37) 0.008 0.073
T2DM-M 0 46 (34) 49 (36) 41 (30)
N-T2DM 0 170 (25) 306 (45) 204 (30) –
Discharge/outpatient:
T2DM-NM 11 (5) 118 (55) 80 (37) 6 (3) 0.169 0.002
T2DM-M 5 (4) 88 (65) 41 (30) 1 (1)
N-T2DM 54 (8) 422 (62) 190 (28) 14 (2) –
12-month follow-up:
T2DM-NM 17 (8) 69 (57) 69 (32) 6 (3) 0.566 0.004
T2DM-M 9 (7) 84 (62) 39 (29) 3 (2)
N-T2DM 88 (13) 415 (61) 156 (23) 20 (3) –
Data are shown as number (percentage). Abbreviations — see Table 1
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cular system. Therefore, while choosing a drug for patients 
with T2DM it is essential to bear in mind that in addition to 
antihyperglycaemic action it can also affect comorbidities 
like HF. 
Many of the biochemical pathways of metformin action 
are well known. It has been suggested that its pleiotropic ef-
fect is associated with its impact on mitochondria: specifically, 
its inhibition of mitochondrial respiratory-chain complex 1. 
Metformin also reduces glucose absorption, suppresses he-
patic gluconeogenesis, amplifies the insulin suppression of 
glucose production, and improves glucose utilisation by skeletal 
muscle and adipose tissue [9]. Additionally, metformin improves 
Figure 1. Metformin treatment in heart failure patients with 
type 2 diabetes mellitus during the first medical contact in 
hospital or the outpatient clinic
Figure 2. Mortality rates at one-year follow-up in heart failure 
patients
Table 4. Mortality and hospitalisation rates at one-year follow-up in heart failure patients, including type 2 diabetes mellitus 
patients treated with or without metformin
Major cause T2DM-NM T2DM-M N-T2DM p (T2DM-NM 
vs. T2DM-M)




HR (95% Cl) 
N-T2DM
Mortality rates:
Total 40 (18.6) 13 (9.6) 75 (10.9) 0.023 0.84  
(0.81–0.88)
0.045 0.88  
(0.86–0.90)
12-month hospitalisation rates:
Total 200 (93.0) 125 (92.6) 532 (78.2) 0.996 0.93  
(0.82–1.04)
0.010 0.83  
(0.77–0.89)
Heart failure 115 (53.5) 54 (40.0) 208 (30.6) 0.433 0.48  
(0.38–0.58)
0.060 0.83  
(0.77–0.89)
Non-HF cardiac disease 36 (16.7) 43 (31.9) 157 (23.1) 0.042 0.23  
(0.17–0.28)
0.511 0.23  
(0.20–0.27)
Renal dysfunction 9 (4.2) 0 13 (1.9) 0.280 0.025  
(0.002–0.049)
0.564 0.021  
(0.008–0.034)
Vascular disease 6 (2.8) 8 (5.9) 13 (1.9) 0.348 0.04  
(0.01–0.07)
0.211 0.03  
(0.02–0.04)
Non-cardiac 30 (14.0) 20 (14.8) 84 (12.4) 0.701 0.14  
(0.10–0.19)
0.107 0.13  
(0.10–0.16)
Data are shown as number (percentage). CI — confidence interval; HR — hazard ratio; other abbreviations — see Table 1
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glucose homeostasis through the action of glucagon-like pep-
tide 1 [10] and opposes the action of the counter-regulatory 
hormone glucagon to inhibit hepatic glucose production [11]. 
Furthermore, metformin induces improvements in insulin ac-
tion through alterations in hepatic lipid homeostasis via the 
inhibition of phosphorylation of acetyl CoA carboxylase by 
AMP-activated protein kinase (AMPK) [12]. 
AMPK activation by metformin or other activators can 
stimulate cardiac glucose uptake and glycolysis independently 
of insulin, bypassing insulin resistance in insulin-resistant 
cardiomyocytes [13]. Additionally, metformin is able to at-
tenuate fibrosis in a canine model of HF, presumably via 
AMPK activation and its inhibitory action on transforming 
growth factor-b expression [14]. It has also been established 
that metformin inhibits myofibroblast differentiation by sup-
pressing reactive oxygen species generation via the inhibition 
of the NADPH oxidase pathway, a process that is probably 
mediated by AMPK [15]. Metformin may also, through af-
Table 5. Mortality rates at one-year follow-up in heart failure patients with chronic kidney dysfunction (CKD) and hepatic  
dysfunction, including type 2 diabetes mellitus patients treated with or without metformin
Treatment Mortality rates p
CKD (n = 60) Without CKD (n = 68)
T2DM-NM 14 (23.8) 21 (15.6) 0.012
T2DM-M 13 (22.2) 8 (7.4) 0.453
N-T2DM 16 (25.9) 39 (7.3) 0.271
Hepatic dysfunction (n = 14) Without hepatic dysfunction (n = 114) p
T2DM-NM 5 (35.7) 35 (17.4) 0.010
T2DM-M 0 (0) 13 (9.8) 0.356
N-T2DM 9 (25.7) 66 (10.2) 0.301
Data are shown as number (percentage). Chronic kidney dysfunction and hepatic dysfunction were diagnosed on the basis of medical documentation. 
Abbreviations — see Table 1
Figure 3. Hospitalisation rates at one-year follow-up in heart failure (HF) patients; CV — cardiovascular
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fecting mitochondrial membrane potential and respiratory 
function, improve function of cardiomyocytes in HF after 
myocardial infarction [16].
Currently, although metformin is seen as a safe and 
well-tolerated drug with the most adverse effects associated 
with the gastrointestinal system (diarrhoea, nausea, and vom-
iting), it is contraindicated in patients with renal or hepatic 
insufficiency and in patients with conditions of circulatory 
dysfunction such as CHF, due to lactic acidosis. Salpeter et al. 
[17] reviewed published reports of controlled trials involving 
metformin that lasted one month or more and were reported 
in November 2002. They found no cases of lactic acidosis in 
36,000 patient-years of exposure to metformin and concluded 
that there was no evidence to support a role for metformin 
in the development of lactic acidosis. A meta-analysis of ob-
servational studies by Eurich et al. [18] found that metformin 
treatment in patients with HF was not associated with any 
increased risk of lactic acidosis. 
A number of clinical trials have assessed the value of 
metformin in the treatment of T2DM in patients with vari-
ous degrees of HF. Eurich et al. [19] recorded fewer deaths 
among subjects receiving metformin than those receiving 
sulphonylurea therapy: 404 (52%) for sulphonylurea mono-
therapy compared to 69 (33%) for metformin monotherapy 
and 263 (31%) for combination therapy. In addition, fewer 
deaths or hospitalisations were also observed: 658 (85%) for 
sulphonylurea monotherapy vs. 160 (77%) for metformin 
monotherapy and 681 (80%) for combination therapy. How-
ever, they reported no difference in time to first hospitalisation 
between the study groups [19]. MacDonald et al. [20] reported 
lower mortality in patients receiving metformin monotherapy 
or metformin with other antidiabetic agents than in patients 
who were not administered antidiabetic drugs; however, the 
use of other antidiabetic drugs or insulin was not associated 
with all-cause mortality. In the present study, the patients 
administered metformin demonstrated significantly lower 
mortality rates than those who were not. Additionally, no 
differences were observed regarding total hospitalisation 
rates. However, it should be highlighted that the hospitalisa-
tion rate due to non-HF cardiac causes was higher in patients 
treated with metformin. 
Our results indicate that patients on metformin therapy 
demonstrated higher values of NYHA classification on admis-
sion to hospital. A study by Lexis et al. [21] found LVEF to 
be 53.1% in a group treated with metformin and 54.8% in 
a placebo group after four months, with no significant differ-
ences observed between the groups regarding creatinine or 
glycated haemoglobin concentration, and, what is also im-
portant, there was no case of lactic acidosis. Lapina et al. [22] 
examined the safety of therapy with metformin and its effect 
on clinical, haemodynamic, functional, and neurohumoral 
status in patients with CHF and T2DM. Patients with light and 
moderate NYHA functional class II–III CHF, LVEF < 45%, and 
T2DM were included in the study, and the total duration of 
the period of treatment and supervision was 12 months. The 
results confirm that metformin is acceptably safe: throughout 
the follow-up period, no cases of lactic acidosis were revealed 
by various comparative analyses. The lack of a positive influ-
ence of metformin on glycaemia at its initial low level was ac-
companied by an improvement of NYHA class, better central 
haemodynamic parameters, improved functional capacities 
of patients, improved quality of life, fewer CHF decompensa-
tions, and a reduced degree of sympathetic adrenergic system 
activation [22].
The results of our study confirm previous observations sug-
gesting that metformin treatment is associated with a lower mor-
tality in T2DM and HF patients. This can be partially explained by 
the reduction in mortality in patients with T2DM in general, but 
there are reports that metformin can also improve the function 
of cardiomyocytes through changes in myocardial metabolic and 
reconstruction processes. Furthermore, the presence of CKD did 
not affect mortality in patients treated with metformin.
Therefore, we support the view of other authors that 
contraindications for metformin should be reconsidered. It 
should be noted that the existing ESC recommendations state 
that metformin is safe for use in patients with HF with reduced 
LVEF and should be the treatment of choice in patients with 
HF, but it is contraindicated in patients with severe renal or he-
patic impairment because of the risk of lactic acidosis [23, 24]. 
However, our results have some limitations due to the 
observational design of the registry study and protocol. First 
of all, the decision to diagnose HF and DM depended on 
locally used diagnostic methods and practice. The presence 
of oedema in patients with acute HF at first medical contact 
could falsify body weight and BMI differences. The differences 
in incidences of renal and hepatic dysfunctions could result 
from contraindications to metformin, and evaluation of the ef-
fect of concurrent hepatic insufficiency on metformin therapy 
was unreliable due to the small number of groups. Similarly, 
large differences in the group size did not allow a reliable as-
sessment of the effect of other antidiabetic drugs on mortality 
and hospitalisations. Moreover, the registry does not collect 
information about the duration of DM.
In conclusion, the results confirm previous observations 
that the use of metformin in patients with different degrees of 
HF and T2DM is associated with a reduction in the risk of death 
and does not increase the number of hospitalisations. However, 
the presence of other contraindications to this drug, such as 
renal failure or liver dysfunction, which increase the frequency 
of hospitalisation, should be considered. These findings sup-
port increasing calls to reduce contraindications for metformin.
Acknowledgements
All participating centres, investigators, and data collection of-
ficers of the Polish section of the ESC HF Long-Term Registry 
are listed below.
www.kardiologiapolska.pl
Arkadiusz Retwiński et al.
1342
WHAT IS NEW?
Despite previous concerns about lactic acidosis associated with the use of metformin, which were reflected in label 
contraindications, some studies suggest that antidiabetic treatment with metformin is safe in patients with heart failure. 
The results of this analysis indicate that metformin treatment is also associated with reduced mortality in heart failure 
patients. Although the incidence of all-cause hospitalisation was similar in both compared groups, the results of this study 
may affect the position of metformin in the pharmacotherapy of diabetics with heart failure and will set the foundation 
for future research.
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